Takeda has stated the verdict is not yet enforceable pending entry of judgment and signaled its intent to file post-trial motions and appeal. The scope of potential liability exposure—potentially exceeding $2.5 billion after trebling and additional proceedings—remains subject to further litigation.
This verdict marks the first jury trial win for private plaintiffs challenging a pay-for-delay settlement under the Supreme Court's FTC v. Actavis framework. Attorneys should monitor whether the result withstands appellate scrutiny and how it reshapes settlement negotiations in patent disputes. The case demonstrates that reverse-payment claims can survive class certification, summary judgment, and trial, creating meaningful exposure for pharmaceutical companies settling patent litigation with generic competitors.